| Title: |
P-2085. Optimizing GAIHN-AR Network Microbiology Laboratory Assets for Early Detection of Carbapenemase-Producing Organisms in Limited Resources Settings: Argentine Experience |
| Authors: |
Corso, Alejandra; Pasteran, Fernando; Marchetti, Paulina; Appendino, Andrea; Pereda, Rosana; Menocal, Alejandra; Sangoy, Ana; Kuzawka, Marilina; Tocho, Eugenia; Cioffi, Antonela; de Mendieta, Juan Manuel; Lucero, Celeste; Colque, Angel M; Alonso, Laura; Iantorno, Paula; Pagano, Irene; Barcelona, Laura |
| Source: |
Open Forum Infectious Diseases ; volume 12, issue Supplement_1 ; ISSN 2328-8957 |
| Publisher Information: |
Oxford University Press (OUP) |
| Publication Year: |
2025 |
| Description: |
Background The Global Action in Healthcare Network-Antimicrobial Resistance Module (GAIHN-AR), led by the U.S. CDC, enhances prevention, detection and response in low-resource hospital settings (LRS) against emerging antimicrobial resistance (AR) threats, with an initial focus on carbapenemase-producing organisms. GAIHN-AR includes a lab. component for improving early AR detection, an infection prevention and control program, and a communication platform for rapid response coordination. We describe the implementation verification/validation of new AR diagnostic methods and their integration into clinical workflow Table Methods Prior to GAIHN-AR initiation in two hospitals in Argentina in January 2023, validation of CPO diagnostic techniques was conducted. For this, reference strains characterized by WGS from the CDC & FDA AR-Bank and Argentina-NRL repository were used. Evaluation followed manufacturer specifications, with GeneXpert also tested with alternative Dacron swabs. Pure colonies were used for validation of all methods, except for GENEXPERT®Carba-R where contrived fecal sample were also used. Methodologies were acceptable with sensitivity, specificity, and precision values ≥ 95%.The following methodologies were verified for carbapenemase detection in Enterobacterales, P. aeruginosa, and Acinetobacter spp. (ACI): (i) GENEXPERT®Carba-R; (ii) NG-Test®CARBA-5 lateral flow (ACI excluded); (iii) CHROMagar mSuperCARBA® chromogenic medium for carbapenem resistance detection; (iv) RAPIDEC® CARBA-NP. Additionally, the GENEXPERT®Carba-R was validated for: i) KPC variants with ceftazidime/avibactam resistance, ii) local circulation metallo-β-lactamase IMP variants Results The methodologies under evaluation achieved performance between 95-100%, except for the IMP variants with GenXpert Carba-R where sensitivity was reduced to 44% (Table). Conclusion Verification/validation process demonstrated that most methods had acceptable performance, allowing integration into lab workflows to facilitate prompt ... |
| Document Type: |
article in journal/newspaper |
| Language: |
English |
| DOI: |
10.1093/ofid/ofae631.2241 |
| Availability: |
https://doi.org/10.1093/ofid/ofae631.2241; https://academic.oup.com/ofid/article-pdf/12/Supplement_1/ofae631.2241/61676451/ofae631.2241.pdf |
| Rights: |
https://creativecommons.org/licenses/by/4.0/ |
| Accession Number: |
edsbas.C1A44208 |
| Database: |
BASE |